Volume 25, Number 2—February 2019
Online Report
Public Health–Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union
Figure

Figure. Funding from the seventh Framework Programme for Research and Technological Development of the European Union to influenza vaccine development. EU, European Union; MVA, modified vaccinia virus Ankara; VLP, virus-like particle.
Page created: January 18, 2019
Page updated: January 18, 2019
Page reviewed: January 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.